Clincosm LogoSign in Get a demo

gastric or gastroesophageal junction adenocarcinoma

Showing 1 - 9 of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

Recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • PD-1 inhibitor
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Aug 9, 2023

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

Active, not recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Jul 4, 2023

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in China (JS001/Placebo, JS001/ combine with Postoperative Adjuvant

Recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • JS001/Placebo
  • JS001/placebo combine with Postoperative Adjuvant Chemotherapy
  • Bengbu, Anhui, China
  • +53 more
Jul 28, 2022

HER2-positive, Locally Advanced Solid Tumor, Immunotherapy Trial in Beijing (sintilimab, Trastuzumab, S-1 plus oxaliplatin)

Not yet recruiting
  • HER2-positive
  • +6 more
  • Beijing, China
    Cancer Hospital & Institute, Chinese Academy of Medical Sciences
Mar 28, 2022

Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma Trial in United States (XmAb®23104, Yervoy®

Recruiting
  • Melanoma (Excluding Uveal Melanoma)
  • +15 more
  • XmAb®23104
  • Yervoy® (ipilimumab)
  • San Diego, California
  • +15 more
Sep 20, 2021

Gastric or Gastroesophageal Junction Adenocarcinoma, AFP Trial in Shenyang (Anti-PD-1 antibody, XELOX)

Recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • AFP
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Apr 13, 2021

Ramucirumab and Paclitaxel in Gastric or Gastroesophageal

Completed
  • Gastric or Gastroesophageal Junction Adenocarcinoma
    • Ansan, Korea, Republic of
    • +56 more
    Mar 22, 2021

    Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (MEDI4736 + tremelimumab, MEDI4736, Tremelimumab)

    Completed
    Has Results
    • Gastric or Gastroesophageal Junction Adenocarcinoma
    • MEDI4736 + tremelimumab
    • +3 more
    • Los Angeles, California
    • +27 more
    Jun 2, 2020